Thermo looks to lab service unit to accelerate growth in 2012

By Nick Taylor

- Last updated on GMT

Related tags Thermo fisher Thermo fisher scientific Thermo electron

Thermo looks to lab service unit to accelerate growth in 2012
Thermo Fisher Scientific is predicting strong growth for its laboratory services unit as clients turn to outsourcing to boost productivity.

After achieving strong growth in clinical trial logistics and packaging Thermo Fisher has rejigged its laboratory business to capture demand for outsourcing. Thermo Fisher expects the new unit, Unity Lab Services, to drive growth in the coming years.

When you look at the [business it] represents…seven to eight per cent of our revenue and growing high-single digits type of growth​”, Marc Casper, CEO of Thermo Fisher, told investors in a call following fourth quarter results.

Thermo Fisher officially opened the unit in early January by combining its instrument and equipment services with its asset management and outsourcing operations. Bringing together these assets will allow clients to have one contract for supply management, consumables, and other services.

The ability to bring all these capabilities together is a real differentiator for us in the marketplace. We see this as yet another vehicle for accelerating our top line growth, not only in 2012, but well into the future​”, Casper said.

Demand for clinical trial logistics and packaging services is also expected to contribute to growth in the coming years. The unit had “very strong growth in 2011​”, Casper said, and the offering “is really resonating with these customers at a time when an increased productivity is critical to their success​”.

Fourth quarter growth

In the fourth quarter double-digit sales growth helped Thermo Fisher increase its operating profit by seven per cent. The laboratory products and services unit’s revenues were up five per cent year-on-year but weakening demand from some sectors restricted growth.

Peter Wilver, chief financial officer of Thermo Fisher, said: “Similar to last quarter, this segment was most affected by the challenging conditions in our academic and government markets, which declined low-single digits in the quarter​.”

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Content provided by Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Follow us


View more